Zacks Research Weighs in on Humana’s Q4 Earnings (NYSE:HUM)

Humana Inc. (NYSE:HUM) – Stock analysts at Zacks Research raised their Q4 2026 EPS estimates for shares of Humana in a report issued on Tuesday, July 14th. Zacks Research analyst Team now forecasts that the insurance provider will earn ($6.07) per share for the quarter, up from their previous estimate of ($6.08). Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Humana’s current full-year earnings is $9.53 per share. Zacks Research also issued estimates for Humana’s Q4 2027 earnings at ($1.91) EPS.

Several other brokerages have also recently commented on HUM. The Goldman Sachs Group raised their target price on Humana from $158.00 to $195.00 and gave the stock a “sell” rating in a research report on Thursday, April 30th. Sanford C. Bernstein reissued an “outperform” rating and issued a $425.00 price objective on shares of Humana in a research note on Wednesday, June 3rd. JPMorgan Chase & Co. raised their price objective on Humana from $214.00 to $316.00 and gave the stock a “neutral” rating in a research report on Monday, June 8th. Leerink Partners lifted their target price on Humana from $185.00 to $255.00 and gave the company a “market perform” rating in a research note on Thursday, April 30th. Finally, Wolfe Research raised Humana from a “hold” rating to a “strong-buy” rating in a research note on Thursday, June 4th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, fifteen have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $325.87.

Humana Price Performance

HUM opened at $400.51 on Thursday. The stock has a fifty day moving average of $354.03 and a 200-day moving average of $260.19. The firm has a market capitalization of $48.09 billion, a P/E ratio of 42.84, a PEG ratio of 2.09 and a beta of 0.71. Humana has a 12-month low of $163.11 and a 12-month high of $428.88. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of 0.66.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, April 29th. The insurance provider reported $10.31 EPS for the quarter, topping analysts’ consensus estimates of $9.97 by $0.34. Humana had a net margin of 0.82% and a return on equity of 10.45%. The firm had revenue of $39.65 billion during the quarter, compared to analyst estimates of $39.37 billion. During the same quarter last year, the business posted $11.58 EPS. The company’s revenue was up 23.5% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.000- EPS.

Hedge Funds Weigh In On Humana

Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in Humana by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 14,261,860 shares of the insurance provider’s stock valued at $3,652,890,000 after purchasing an additional 106,030 shares in the last quarter. Capital International Investors raised its stake in shares of Humana by 113.9% during the 4th quarter. Capital International Investors now owns 5,818,008 shares of the insurance provider’s stock worth $1,490,239,000 after purchasing an additional 3,097,571 shares in the last quarter. Pzena Investment Management LLC raised its stake in shares of Humana by 34.3% during the 1st quarter. Pzena Investment Management LLC now owns 5,470,982 shares of the insurance provider’s stock worth $948,614,000 after purchasing an additional 1,398,774 shares in the last quarter. State Street Corp lifted its holdings in shares of Humana by 1.8% during the 4th quarter. State Street Corp now owns 5,462,549 shares of the insurance provider’s stock valued at $1,403,877,000 after buying an additional 97,211 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its holdings in shares of Humana by 28.9% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,496,775 shares of the insurance provider’s stock valued at $1,151,759,000 after buying an additional 1,008,514 shares during the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.